|
||
Poliwit Dosage |
||
Childn 1-3 yr 0.5 mL once daily. Infant 6-12 mth 0.25 mL once daily.
Poliwit (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers. Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events. There were no significant effects on QTc intervals, and no reports of sedation or syncope. No effects on plasma concentrations of cimetidine or ketoconazole were observed. Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone. The clinical relevance of this difference is unknown. These above findings are summarized in TABLE 1.
TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of Poliwit and Descarboethoxyloratadine After 10 Days of Coadministration (Poliwit 10 mg) in Normal Volunteers | ||
Poliwit | Descarboethoxyloratadine | |
---|---|---|
Erythromycin (500 mg q8h) | + 40% | +46% |
Cimetidine (300 mg qid) | +103% | + 6% |
Ketoconazole (200 mg q12h) | +307% | +73% |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|